N/A N=122 Effectiveness of a Group Lifestyle Balance Class in a Military Population
Primary Prevention
Primary: Weight — 191.47; 198.08; 204.08 pounds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=217 Patient Perception Questionnaire Validation
Obstructive Sleep Apnea
Primary: To Determine the Association of the Participants Baseline PPQ (Patient Perception Questionnaire) Responses to Predict Adherence to CPAP Treatment at 90 Days. — .04; .14…
N/A N=67 China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
Aortic Stenosis · Symptomatic Aortic Stenosis · Aortic Regurgitation
Primary: All-cause Mortality — 4 Participants
N/A N=8 Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease
Parkinson Disease · Mild Cognitive Impairment
Primary: Mean Change in Cognitive Function — -0.6960; -0.6095; 0.6018; 0.6018 z-score
Phase 2 N=720 Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
Influenza A Virus, H5N1 Subtype
Primary: Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series — 43; 32; 35; 37 Events
N/A N=130 McGrath Videolaryngoscopy and Direct Laryngoscopy in Morbidly Obese Patients
Morbid Obesity
Primary: Classification of Glottis Visualization — 45; 23; 11; 16 Participants — p=<0.01
Phase 3 N=506 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
Relapsing Remitting Multiple Sclerosis
Primary: Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B…
N/A N=250 Anxiety and Distress Levels in Women With Suspected Endometrial Cancer
Endometrial Cancer · Cancer · Uterine Cancer
Primary: Anxiety Score for Patients Attending Clinic — 6 score on a scale
Phase 2 N=34 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
Phase 3 N=702 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs) — 5 Participants
N/A N=12 Internal Jugular Vein Flow in the Sitting Position
Jugular Venous Flow
Primary: Internal Jugular Venous Flow — 0.04; 0.4; 0.04; 0.21 cm2
N/A N=48 Quadratus Lumborum Block Versus Transversus Abdominus Plane Block for Pain Management After Donor Nephrectomy
Kidney Donor
Primary: Average Pain Score — 5.2; 5.1 score on a scale — p=.883
N/A N=5 Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning
Prostate Cancer
Primary: Number of Participants Who Had Biopsies With True Positives Between Biopsy Tissue and Intraprostatic MRI — 2 Participants
N/A N=150 Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue?
Endometrial Neoplasms · Endometrial Cancer · Endometrial Hyperplasia
Primary: Diagnostic Ability of iKnife (REIMS) in Detection of Cancer and Pre-cancer in Endometrial Biopsy Specimens — 79; 96; 93; 86 percentage
N/A N=54 Depression Therapy to Improve Cardiovascular Risk in HIV
Depression · HIV
Primary: Change in Brachial Artery Flow-mediated Dilation From Baseline to Week 12 — -0.47; 0.29 absolute percent change — p=0.32